Glucagon-Like Peptide-1 Peptide Industry: Market Trends, Brand Comparison, and Product Analysis
Abstract: Glucagon-like peptide-1 (GLP-1) is a 30-31 amino acid incretin hormone driving a multi-billion dollar peptide industry, primarily for type 2 diabetes and obesity. Market trends show 15-20% annual growth, led by semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly). Brand comparison reveals efficacy differences: semaglutide offers 15% weight loss; tirzepatide, 22%. Product analysis highlights stability vs. cost trade-offs: liraglutide requires daily injection, while semaglutide enables weekly dosing. Key parameters include purity (>98% by HPLC) and bioactivity. Industry challenges include cold-chain logistics (2-8°C) and regulatory compliance (FDA/EMA). Selection criteria prioritize GMP-certified factories, third-party testing certificates, and peptide sequence verification. The sector projects $100B by 2030, driven by oral formulations and expanded indications.